AK MEDICAL (01789) released its annual performance with a net profit attributable to shareholders of 339 million yuan, a year-on-year increase of 23.8%.

AK MEDICAL (01789) released its performance for the year ending December 31, 2025. The group achieved revenue of RMB 1.482 billion (in the same unit), a year-on-year increase of 10.1%; net profit attributable to company's equity shareholders for the year was RMB 339 million, a year-on-year increase of 23.8%; basic earnings per share was RMB 0.304, and proposed a final dividend of 11.8 HK cents per share. In 2025, driven by the policy of centralized drug procurement, the import substitution was further accelerated, leading to a continuous increase in demand for the company's surgical products. The rapid growth in surgical volume, along with the push of the digital orthopedic full-process solutions, further enhanced the coverage of the company's products in hospitals, resulting in increased sales. At the same time, the group achieved significant growth in overseas revenue and digital orthopedic intelligent products and services through active market development. The group achieved a net profit of RMB 339 million for the year ending December 31, 2025, a significant increase of 23.8% compared to the same period in 2024. The significant growth in profit is mainly attributed to the increase in revenue and the improvement in gross profit margin due to the increase in overseas and digital orthopedic custom products and services revenue.